Shares in Ireland’s vaccine human testing firm climb 352% in 2020

A small Irish-based laboratory that conducts live trials testing potential Covid-19 and other vaccines for the British government is the biggest winner on the Irish stock exchange this year, with the stock gaining 352% during the pandemic.

That performance puts it up there among the best stock performances across Europe, beating in percentage terms even the gains posted by Germany’s BionNTech, led by Professor Ugur Salin, who has helped produce one of the two potentially most successful vaccines.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Venn Life Sciences: Medical writing

Team experience Small dedicated team of Senior Medical Writers and Clinical Trial Assistant with total team experience in clinical and regulatory writing of more than 75 years In addition, Venn is working with a flexible shell

Open Orphan Plc

RSV Human Challenge Study
as a tool for a break-through designation

IntroductionAn international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified vaccinia virus Ankara RSV vaccine candidate.

Open Orphan Plc

Open Orphan to commence influenza human challenge study

Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical trials – has announced that its

Open Orphan Plc

Cocrystal Pharma partners with hVIVO

A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral candidate, CC-42344. Housed in hVIVO’s state-of-the-art

Open Orphan Plc

From bench to clinic: Hurdles in gene therapy development

Gene therapy offers significant potential to treat diseases with high unmet medical need. However, the unique nature of these therapies poses challenges in product development, namely: safety concerns, efficacy issues, or obstacles related to Chemistry, Manufacturing and Controls

Open Orphan Plc

What is FluCamp?

FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses. Ultimately, the more that we understand about how viruses affect the human immune system, the more quickly we can

Open Orphan Plc

Open Orphan’s hVIVO signs £6.2m human challenge study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has

Open Orphan Plc

Where’s the demand in human challenge clinical trials?

In the early months of the pandemic, human challenge clinical trials drew amplified public interest on its potential to accelerate the hunt for Covid-19 vaccines. Fast forward two years later, while mainstream media buzz around this trial

Open Orphan Plc

The lowdown on hay fever

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or

Open Orphan Plc

How to stay healthy in your 20’s

In your 20’s life tends to change dramatically – and it can be easy to let your health take a back seat. However, it is a period in which is vital to establish a healthy lifestyle,

Open Orphan Plc

CMC team capabilities New Chemical Entities

For 20+ years, members of the CMC (Chemistry Manufacturing and Control) team have supported and are supporting numerous pharmaceutical companies to ensure the timely development and manufacture of high-quality drug substances and drug products for non-clinical-

Open Orphan Plc

Omicron: The Lowdown

The COVID pandemic started at the turn of 2020. The virus was first detected in Wuhan, China and since then has spread around the globe and mutated into several different strains. As of June 2022, the

Open Orphan Plc

The best supplements to support your health

The winter season can wreak havoc on your immune system, particularly when we spend much of our time huddled indoors, and our diet may become a little more carbohydrate based. Fortunately, science has allowed us to

Open Orphan Plc

Research backs the annual flu jab

The flu jab has encountered some controversy during its time in circulation. However, recent research suggests that some of these rumoured negative effects may in fact not be true – and actually, the opposite might apply.

Open Orphan Plc

CMC team capabilities for biologics

For 20+ years, members of the CMC (Chemistry, Manufacturing and Controls) team supported numerous (bio)pharmaceutical and biotechnological companies to ensure the development and manufacture of high-quality drug substances and drug products for » CMC management and